(Q47217947)

11 January 2018

title

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application (English)

1 reference

11 January 2018

1 reference

6

1 reference

11 January 2018

Riccardo Gavioli

7

1 reference

11 January 2018

Katia Sparnacci

14

1 reference

11 January 2018

Michele Laus

15

1 reference

11 January 2018

Luisa Tondelli

Luisa Tondelli

16

0 references

Laura Chiarantini

Laura Chiarantini

9

0 references

Antonella Caputo

Antonella Caputo

1

0 references

Barbara Ensoli

Barbara Ensoli

17

0 references

Aurelio Cafaro

13

Aurelio Cafaro

1 reference

11 January 2018

Egidio Brocca-Cofano

2

Egidio Brocca-Cofano

1 reference

11 January 2018

Arianna Castaldello

3

Arianna Castaldello

1 reference

11 January 2018

Rita De Michele

4

Rita De Michele

1 reference

11 January 2018

Aurora Cerasi

10

Aurora Cerasi

1 reference

11 January 2018

author name string

Giuseppe Altavilla

5

1 reference

11 January 2018

Ulrika Rolen

8

1 reference

11 January 2018

Sabrina Dominici

11

1 reference

11 January 2018

Mauro Magnani

12

1 reference

11 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

11 January 2018

published in

Vaccine

1 reference

11 January 2018

volume

22

1 reference

11 January 2018

page(s)

2910-2924

1 reference

11 January 2018

issue

21-22

1 reference

11 January 2018

Recent advances in vaccine adjuvants for systemic and mucosal administration

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Controlled-release vaccines--biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Potential of polymer microencapsulation technology for vaccine innovation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Aspects of the design and delivery of microparticles for vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Recent developments in vaccine delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Vaccination with Rev and Tat against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Redistribution of DNA topoisomerase II beta after in vitro stabilization of human erythroleukemic nuclei by heat or Cu++ revealed by confocal microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Microspheres and nanoparticles used in ocular delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Controlled delivery of antigens and adjuvants in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Distribution and elimination of poly(methyl methacrylate) nanoparticles after subcutaneous administration to rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Distribution and Elimination of Poly(methyl-2-14C-methacrylate) Nanoparticle Radioactivity after Injection in Rats and Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

New advances in microsphere-based single-dose vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Core–shell microspheres by dispersion polymerization as drug delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Protein instability in poly(lactic-co-glycolic acid) microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.12.025

1 reference

11 January 2018

release_ovn2jr642fg67oiduc63ujltuy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ovn2jr642fg67oiduc63ujltuy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15246628

1 reference

11 January 2018